TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01409564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
Study: NCT01413191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: 10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study: NCT01280916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy
Description: 8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
Study: NCT00846131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Randomized to Y-90 ± Sorafenib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yttrium-90 (Y-90)
Description: Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y-90)
Description: Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
Study: NCT00280462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (drug)
Description: Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (drug)
Description: Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine (drug)
Description: Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginin (drug)
Description: L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginin (drug)
Description: L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Arginin (drug)
Description: L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01036035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Comparison of different dosages of drug
Study: NCT01259076

Intervention type: PROCEDURE
Intervention: digital mammography
Description: Undergo digital mammography at baseline and 1 year later.

Intervention type: PROCEDURE
Intervention: digital mammography
Description: Undergo digital mammography at baseline and 1 year later.

Intervention type: PROCEDURE
Intervention: conventional surgery
Description: Undergo gastric bypass surgery
Study: NCT02446418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
Study: NCT01716338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01036035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: Comparison of different dosages of drug
Study: NCT04080479

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quadriceps Muscle Layer Fitness
Description: The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quadriceps Muscle Layer Fitness
Description: The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle Strength
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle Strength
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acute Physiology and Chronic Health Evaluation
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acute Physiology and Chronic Health Evaluation
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nutritional Risk Screening
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nutritional Risk Screening
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Energy and Protein Intake
Description: The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Energy and Protein Intake
Description: The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
Study: NCT01420874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRBi armed ATC Infusions
Description: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
Study: NCT04120857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Stretching
Description: 60 minutes fo gentle stretching twice weekly for 8 weeks
Study: NCT01893879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for study drug
Description: Given PO
Study: NCT02281487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy plus Tubectomy
Description: hysterectomy with tubectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: standard hysterectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light microscopy
Description: analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
Study: NCT01463930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational audiovisual videodisc and medical verbal information
Description: General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical verbal information
Description: General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
Study: NCT03135444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSA TOOL
Description: Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revised PSA TOOL
Description: Patients will be given the revised PSA TOOL, after providers have given their initial feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informal Interview
Description: Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
Study: NCT01036035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THVD-201
Description: Comparison of different dosages of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THVD-201
Description: Comparison of different dosages of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Comparison of different dosages of drug
Study: NCT04876625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myTAP oral appliance plus mouth shield
Description: myTAP anti-snoring oral appliance worn with mouth shield for all 8-weeks; the mouth shield is a comfort accessory that fits over the oral appliance itself and extends into the oral vestibule.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: myTAP oral appliance alone for first 4 weeks
Description: myTAP anti-snoring oral appliance worn alone for first 4 weeks followed by wearing it for 4 weeks with the mouth shield
Study: NCT04234581

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysulin
Description: Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lysulin
Description: Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
Study: NCT03135444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informal Interview
Description: Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
Study: NCT01027221

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant photon radiation
Description: single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
Study: NCT01390779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Description: Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
Study: NCT04046354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Percutaneous Microwave Ablation
Description: Ultrasound-guided Percutaneous Microwave Ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Percutaneous Radiofrequency Ablation
Description: Ultrasound-guided Percutaneous Radiofrequency Ablation
Study: NCT01893879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (RS)2-(3-benzoylphenyl)-propionic acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02865681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur
Description: Nasal versus injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopur
Description: Nasal versus injectable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synarel
Description: nasal
Study: NCT02937298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Meal
Description: This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry Treatment
Description: This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
Study: NCT02865681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synarel
Description: nasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG trigger
Description: injectable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Oral
Study: NCT02937298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea Buckthorn Treatment
Description: This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Garlic Treatment
Description: This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
Study: NCT01027221

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant photon radiation
Description: single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant photon radiation
Description: single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
Study: NCT00005622

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)

Intervention type: RADIATION
Group type: OTHER
Intervention: TBI
Description: FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
Study: NCT02003612

Intervention type: OTHER
Intervention: Not applicable - observational study
Description: No intervention exists as this is a retrospective observational study
Study: NCT04893603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve System
Description: Procedure: Transcatheter aortic valve replacement
Study: NCT01238770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I.
Study: NCT01426984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: a capsule containing 20 mg
Study: NCT01128348

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient advocate
Description: patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient advocate
Description: patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
Study: NCT00717522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study: NCT01069302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel loading 600mg and maintenance 150mg for 7days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel loading 600mg and maintenance 75mg for 7days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel loading 300mg and maintenance 150mg for 7days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel loading 300mg and maintenance 75mg for 7days
Study: NCT01384500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline in tube cuff
Description: Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
Study: NCT01620502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acids
Description: A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
Study: NCT00387413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
Study: NCT01577329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
Study: NCT00387413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189254
Description: Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189254
Description: Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189254 Placebo
Description: Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189254 Placebo
Description: Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189254 Placebo
Description: Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189254 Placebo
Description: Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Placebo
Description: Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
Study: NCT00486148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula (with GOS)
Description: Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
Study: NCT01770626

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Nutrition
Description: Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).